The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Violin - I don’t think anyone should be using the FARN product BEXMAB as a “potential blueprint” for SCIB. For a start, FARN have only recently had their pants pulled down due to the need to disclose events of default on debt obligations to their lender. Saying that Scancell are better funded is somewhat of an understatement and will clearly have an impact on development & commercialisation.
So personally, I don’t see any correlation and really hope none exists.
Good debate on SC129 but it took a number of twists & turns away from the original point.
That was purely and simply when, or if, there might be a milestone payment if Genmab decide to take SC129 into the clinic. It wasn’t about what might or might not happen 5 years down the line and the stab in the dark $10M suggestion makes that crystal clear combined with the comment that such a payment would help underpin the SP, not send it into orbit.
Violin - “and LD didn't speak at the AGM as if Genmab was anyway near milestone payments”
From the January Interims RNS issued to the market:.
“Development of SC129, out licensed to Genmab, continues on track towards potential clinical development.”
On track will do for me.
Good to see store expansion strategy continuing. Effectively one store per month for the 5 month period and so reasonable to think another 5+ before calendar year end.
Wonder how close we might be to news that Genmab will be taking SC129 into the clinic. It's already been discussed on here that if that happens, it would be a big surprise if contractually, that didn't trigger a further milestone payment. Stab in the dark $10M+ dollars at that point in time. Remember that Lindy was bullish about its prospects in the presentation complimenting the Interims.
That would be cool and underpin the SP for other newsflow anticipated this year. Just around the corner? Maybe!
WTP - my take………
It’s broadly about paying someone to make sure regulatory submissions are faultless and delivered on time.
Pretty pointless surely, to waste money fulfilling that role, if there are zero plans on the table, to submit anything to regulators?
Yup. Maybe this link helps.
https://www.abstractsonline.com/pp8/#!/20272/presentation/11402